Materia, the mother company of Materia Malta, announced that it has commenced sales of the first medical cannabis flower produced at its EU GMP certified manufacturing site.
‘Carbasi Verde’, the company’s inaugural product, can now be purchased from pharmacies all over the islands and will be shipped out to Germany and the UK.
“The journey began in earnest over two years ago, so we’re elated to be offering patients Materia manufactured and branded medical cannabis,” Materia’s Europe Managing Director, Nick Pateras, said.
“Out Maltese site is truly state-of-the-art, and with our team’s deep pharmaceuticals expertise we’re confident that Materia Malta will become one of the most important production facilities in Europe’s cannabis supply chain,” he continued.
‘Carbasi Verde’ was released into the market with a potency of 21.7% THC, following successful completion of Materia Malta’s first production cycle.
“Materia has been at the forefront of Malta’s cannabis industry since we moved quickly to become a European leader in this field,” Malta Enterprise CEO Kurt Farrugia said, congratulating the company.
“We’re extremely proud to see locally produced medicinal products available to Maltese patients and are excited to continue supporting Materia’s talented team as the company expands its presence across the content,” he concluded.
The appointments enhance the firm's capabilities in capital markets, investment services, and corporate law.
The research, which surveyed both employees and finance leaders, highlights the negative impact that restricted budget access can have on ...
Over the years, she has held numerous directorships and leadership positions across local businesses, governmental organisations, and non-profit entities.
Each time a user enters data into a GenAI platform, the information becomes part of the system's learning model.